Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IpsenCHIX:IPNP 93 EV-to-EBIT is 20.42 as of Aug. 02, 2026, which is 48% above its 10-year median of 13.80. GuruFocus rates CHIX:IPNP with a GF Score™ of 93/100 and a GF Value™ of €128.22 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 691 Drug Manufacturers companies, Ipsen ranks worse than 59.19% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ipsen's Enterprise Value is €12,720 Mil.
Ipsen's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €623 Mil. Therefore, Ipsen's EV-to-EBIT for today is 20.42.
The historical rank and industry rank for Ipsen's EV-to-EBIT or its related term are showing as below:
CHIX:IPNp'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1057.75 Med: 13.8 Max: 33.56
Current: 20.42
During the past 13 years, the highest EV-to-EBIT of Ipsen was 33.56. The lowest was -1057.75. And the median was 13.80.
CHIX:IPNp's EV-to-EBIT is ranked worse than 59.19% of 691
companies
in the Drug Manufacturers industry
Industry Median: 15.69
vs CHIX:IPNp: 20.42
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ipsen's Enterprise Value for the quarter that ended in Dec. 2025 was €9,207 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ipsen's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €623 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipsen EV-to-EBIT Related Terms
Ipsen EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ipsen's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:IPNP vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipsen EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipsen's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ipsen's EV-to-EBIT falls into.
Ipsen's current Enterprise Value is €12,720 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ipsen's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €623 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipsen (CHIX:IPNP) has a EV-to-EBIT of 20.42 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ipsen and its competitors. This is 48% above median its historical median of 13.80. According to the industry distribution chart, Ipsen ranks #409 out of 691 companies in the Drug Manufacturers industry, placing it in the top 59.2%.
Is Ipsen's EV-to-EBIT too high?
Ipsen's current EV-to-EBIT of 20.42 is 48% above median its 10-year median of 13.80. The Drug Manufacturers industry median EV-to-EBIT is 15.69. Ipsen's value of 20.42 is 30.1% above this industry median. Based on the distribution chart, Ipsen ranks #409 out of 691 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ipsen has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipsen's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipsen ranks #409 out of 691 companies for EV-to-EBIT. This places Ipsen in the lower half of its industry. The industry median EV-to-EBIT is 15.69. Ipsen's value of 20.42 is 30.1% above this benchmark. While the company's 10-year median is 13.80 vs. the industry median of 15.69, Ipsen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.69, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipsen's current EV-to-EBIT of 20.42 is 30.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ipsen and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipsen's current EV-to-EBIT is 20.42, which is 48% above median its own 10-year median of 13.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Based on GuruFocus' analysis, Ipsen (CHIX:IPNP) is currently considered Modestly Overvalued. The stock's GF Value™ is €128.22, compared to a current price of €158.95 — trading 24% above its estimated fair value. The current EV-to-EBIT is 20.42, which is 48% above median its 10-year median of 13.80 and 30.1% above the Drug Manufacturers industry median of 15.69. Ipsen's overall GF Score™ is 93/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ipsen (CHIX:IPNP), the current EV-to-EBIT is 20.42 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipsen (CHIX:IPNP) Overvalued in 2026?
Based on GuruFocus' analysis, Ipsen stock appears to be overvalued.
The current stock price of €158.95 is trading 24% above its estimated GF Value™ of €128.22.
GuruFocus considers Ipsen to be Modestly Overvalued.
Key valuation signals for CHIX:IPNP:
EV-to-EBIT: 20.42 (48% above median its 10-year median of 13.80)
GF Value™: €128.22 vs. price of €158.95 (24% above fair value)
Industry Position: 30.1% above the Drug Manufacturers median (#409 of 691)
No single metric tells the full story. See the CHIX:IPNP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
93GF Score
Get the complete analysis for CHIX:IPNP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:IPNP has been successfully added to your 
